Soleno Therapeutics, Inc.

NasdaqCM SLNO

Soleno Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 532.27

Soleno Therapeutics, Inc. Price to Sales Ratio (P/S) is 532.27 on January 14, 2025, a 9.39% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Soleno Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 740.78 on November 11, 2024, which is 39.17% above the current Price to Sales Ratio (P/S).
Soleno Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 428.85 on April 12, 2024, which is -19.43% below the current Price to Sales Ratio (P/S).
Soleno Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 562.58.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: SLNO

Soleno Therapeutics, Inc.

CEO	Dr. Anish Bhatnagar M.D.
IPO Date	Nov. 13, 2014
Location	United States
Headquarters	203 Redwood Shores Parkway
Employees	33
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Key trends

Past 5 years